As European probe advances, Takeda, Shire deal expected to clear — 3 insights

Shire and Takeda expect their deal will earn European Commission approval, according to a SeekingAlpha report.

Advertisement

Here’s what you should know:

1. The European Commission’s probe was in its 16th day as of Oct. 22. The commission is expected to inform Takeda and Shire either formally or informally about the stance of their deal.

2. Both companies expect the deal will earn regulatory approval.

3. Takeda’s $62 billion acquisition will make it one of the world’s largest and most indebted drug makers.

More articles on supply chain:
Optum’s revenues grow to $25.4B in Q3 & more — 8 ASC company key notes
CMS investigating HealthCare.gov data breach affecting 75K individuals
New York ASC partners with payer to deliver region’s 1st outpatient hip replacements

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply chain

Advertisement

Comments are closed.